491 related articles for article (PubMed ID: 25154927)
1. Cationic amphipathic D-enantiomeric antimicrobial peptides with in vitro and ex vivo activity against drug-resistant Mycobacterium tuberculosis.
Lan Y; Lam JT; Siu GK; Yam WC; Mason AJ; Lam JK
Tuberculosis (Edinb); 2014 Dec; 94(6):678-89. PubMed ID: 25154927
[TBL] [Abstract][Full Text] [Related]
2. Potent cationic antimicrobial peptides against Mycobacterium tuberculosis in vitro.
Silva S; Santos-Silva A; da Costa JMC; Vale N
J Glob Antimicrob Resist; 2019 Dec; 19():132-135. PubMed ID: 31154008
[TBL] [Abstract][Full Text] [Related]
3. SILA 421, an inhibitor of efflux pumps of cancer cells, enhances the killing of intracellular extensively drug-resistant tuberculosis (XDR-TB).
Martins M; Viveiros M; Ramos J; Couto I; Molnar J; Boeree M; Amaral L
Int J Antimicrob Agents; 2009 May; 33(5):479-82. PubMed ID: 19155160
[TBL] [Abstract][Full Text] [Related]
4. Inhalable spray-dried formulation of D-LAK antimicrobial peptides targeting tuberculosis.
Kwok PC; Grabarek A; Chow MY; Lan Y; Li JC; Casettari L; Mason AJ; Lam JK
Int J Pharm; 2015 Aug; 491(1-2):367-74. PubMed ID: 26151107
[TBL] [Abstract][Full Text] [Related]
5. Targeting human macrophages for enhanced killing of intracellular XDR-TB and MDR-TB.
Martins M; Viveiros M; Couto I; Amaral L
Int J Tuberc Lung Dis; 2009 May; 13(5):569-73. PubMed ID: 19383188
[TBL] [Abstract][Full Text] [Related]
6. Synergistic combination of antimicrobial peptide and isoniazid as inhalable dry powder formulation against multi-drug resistant tuberculosis.
Shao Z; Tam KK; Achalla VPK; Woon ECY; Mason AJ; Chow SF; Yam WC; Lam JKW
Int J Pharm; 2024 Apr; 654():123960. PubMed ID: 38447778
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Polyphenolic Profile and Antibacterial Activity of Pomegranate Juice in Combination with Rifampin (R) against MDR-TB Clinical Isolates.
AlMatar M; Var I; Kayar B; Eker E; Kafkas E; Zarifikhosroshahi M; Köksal F
Curr Pharm Biotechnol; 2019; 20(4):317-326. PubMed ID: 30854955
[TBL] [Abstract][Full Text] [Related]
8. Concomitant increases in spectrum and level of drug resistance in Mycobacterium tuberculosis isolates.
Sun Z; Zhang J; Song H; Zhang X; Li Y; Tian M; Liu Y; Zhao Y; Li C
Int J Tuberc Lung Dis; 2010 Nov; 14(11):1436-41, i. PubMed ID: 20937184
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of tetracycline analogs against multidrug-resistant and extensive drug resistance clinical isolates of Mycobacterium tuberculosis.
Zhang C; Ouyang Q; Zhou X; Huang Y; Zeng Y; Deng L; Lin D; Zheng W
Tuberculosis (Edinb); 2023 May; 140():102336. PubMed ID: 36963294
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy.
de Knegt GJ; ten Kate MT; van Soolingen D; Aarnoutse R; Boeree MJ; Bakker-Woudenberg IA; de Steenwinkel JE
Tuberculosis (Edinb); 2014 Dec; 94(6):701-7. PubMed ID: 25621361
[TBL] [Abstract][Full Text] [Related]
11. In vitro interaction profiles of the new antitubercular drugs bedaquiline and delamanid with moxifloxacin against clinical Mycobacterium tuberculosis isolates.
Chandramohan Y; Padmanaban V; Bethunaickan R; Tripathy S; Swaminathan S; Ranganathan UD
J Glob Antimicrob Resist; 2019 Dec; 19():348-353. PubMed ID: 31226332
[TBL] [Abstract][Full Text] [Related]
12. Preliminary evaluation of anti-tuberculosis potential of siderophores against drug-resistant Mycobacterium tuberculosis by mycobacteria growth indicator tube-drug sensitivity test.
Gokarn K; Pal RB
BMC Complement Altern Med; 2017 Mar; 17(1):161. PubMed ID: 28327117
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Park SK; Kim JH; Kang H; Cho JS; Smego RA
Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
[TBL] [Abstract][Full Text] [Related]
14. Early detection of multidrug- and pre-extensively drug-resistant tuberculosis from smear-positive sputum by direct sequencing.
Chen J; Peng P; Du Y; Ren Y; Chen L; Rao Y; Wang W
BMC Infect Dis; 2017 Apr; 17(1):300. PubMed ID: 28438132
[TBL] [Abstract][Full Text] [Related]
15. Drug Resistance Characteristics of
Wu X; Yang J; Tan G; Liu H; Liu Y; Guo Y; Gao R; Wan B; Yu F
Front Cell Infect Microbiol; 2019; 9():345. PubMed ID: 31828045
[No Abstract] [Full Text] [Related]
16. Comparison of
Zong Z; Jing W; Shi J; Wen S; Zhang T; Huo F; Shang Y; Liang Q; Huang H; Pang Y
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29844043
[TBL] [Abstract][Full Text] [Related]
17. Drug resistance mechanisms and drug susceptibility testing for tuberculosis.
Miotto P; Zhang Y; Cirillo DM; Yam WC
Respirology; 2018 Dec; 23(12):1098-1113. PubMed ID: 30189463
[TBL] [Abstract][Full Text] [Related]
18. Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-Natal.
Cohen KA; Abeel T; Manson McGuire A; Desjardins CA; Munsamy V; Shea TP; Walker BJ; Bantubani N; Almeida DV; Alvarado L; Chapman SB; Mvelase NR; Duffy EY; Fitzgerald MG; Govender P; Gujja S; Hamilton S; Howarth C; Larimer JD; Maharaj K; Pearson MD; Priest ME; Zeng Q; Padayatchi N; Grosset J; Young SK; Wortman J; Mlisana KP; O'Donnell MR; Birren BW; Bishai WR; Pym AS; Earl AM
PLoS Med; 2015 Sep; 12(9):e1001880. PubMed ID: 26418737
[TBL] [Abstract][Full Text] [Related]
19. Classical against molecular-genetic methods for susceptibility testing of antituberculotics.
Porvaznik I; Mokry J; Solovic I
Adv Exp Med Biol; 2015; 835():15-22. PubMed ID: 25252893
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of (-)-deoxypergularinine, on its own and in combination with anti-tubercular drugs, against resistant strains of Mycobacterium tuberculosis.
Nam KW; Jang WS; Jyoti MA; Kim S; Lee BE; Song HY
Phytomedicine; 2016 May; 23(5):578-82. PubMed ID: 27064017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
